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Abstract
The burden of chronic obstructive pulmonary disease on intensive
care is heavy, but newer modalities of treatment are now available
to improve outcomes. Cardiac-based research continues to
generate new drugs and tests to better outcome and aid in early
diagnosis. And how do various intensive care interventions
compare in improving clinical and functional outcomes?
Novel therapies in chronic obstructive
pulmonary disease
Chronic obstructive pulmonary disease (COPD) continues to
be a major medical problem. With no curative therapy being
available, management of severe exacerbations of COPD
should be directed at relieving symptoms and restoring
functional capacity [1]. Mortality from COPD continues to rise
and the World Health Organisation predicts it will be the third
leading cause of death by 2030 [2]. There is current
evidence suggesting that quality improvement interventions
ought to be focussed at recognition of complications and
treatment of the same [3].
We examine a randomized double-blind, cross-over study
published by Israeli investigators Staz and Rav [4] looking at
the effect of N-acetylcysteine (NAC) on airflow limitation in
COPD. Twenty-four moderate to severe COPD patients were
randomized to placebo or nebulised NAC (1,200 mg per day)
treatment twice daily for 6 weeks. This was followed by a
2-week washout period and patients were crossed over to
alternative therapy for a further 6 weeks. Evaluation of forced
vital capacity, inspiratory capacity and other parameters was
made after each 6-week treatment. The results showed that
forced vital capacity and inspiratory capacity were higher,
especially after exercise, in the NAC group compared with
placebo. Furthermore, endurance time was longer after NAC
treatment compared with placebo treatment. They concluded
that use of NAC in moderate to severe COPD patients
produces a beneficial effect on physical performance,
probably due to reduction in dynamic hyperinflation with a
relatively short course of treatment. It is impossible to
extrapolate these data to the ICU population, but this paper
may ignite renewed interest in NAC therapy, possibly
reducing the need for invasive ventilation or the number of
ventilator days. Only further studies will tell.
Roflumilast is a new phosphodiesterase-4 inhibitor, and may
offer some hope for patients with moderate to severe COPD.
The Lancet published two randomised clinical trials suggesting
that this new agent decreases COPD exacerbations and the
need for adjuvant corticosteroid therapy, improves lung
function tests and reported functional capacity when compared
with placebo [5,6]. It seems likely that roflumilast could become
an important concomitant therapy in certain COPD subsets.
Cardiac chemicals
Acute myocardial infarction is often a diagnostic challenge in
the critically ill. A recent muticentre, emergency-room-based
study by Reichlin and colleagues [7] looked at the difference
between sensitive troponin assays and standard troponin
assays. Cardiac troponin levels were determined in a blinded
fashion with the use of four sensitive assays and a standard
assay. The final diagnosis was adjudicated by two indepen-
dent cardiologists. Acute myocardial infarction was diag-
nosed in 17% of cases and accuracy was ascertained using
AUC (area under the receiver operating characteristic curve).
The sensitive assays had significant 20 to 25% increased
sensitivity compared to standard assays. The authors
concluded that this new diagnostic assay should substantially
improve the early detection of acute myocardial infarction
and, therefore, outcome.
Atrial fibrillation is the direct cause of one in four strokes in
the over 80 year olds. Treating individuals with warfarin
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reduces the rate of stroke for those who have atrial fibrillation
by approximately one-half to two- thirds [8]. But the increased
risk of haemorrahge and need for monitoring has sparked
much research, and a recent study tested a new direct
thrombin inhibitor, dabigatran, against warfarin [9]. Connolly
and colleagues [9] employed a non-inferiority trial, randomly
assigning 18,113 patients with atrial fibrillation and a risk of
stroke to receive, in a blinded fashion, fixed doses of
dabigatran (110 mg or 150 mg twice daily) or, in an un-
blinded fashion, adjusted-dose warfarin. The median duration
of the follow-up period was 2 years. The primary outcome
was stroke or systemic embolism. The study boasts of a
favourable outcome towards dabigatran in terms of both
preventing stroke/systemic embolism and lesser rates of
major haemorrhage.
Intensive care outcomes
Burtin and colleagues [10] investigated whether a daily
exercise session, using a bedside cycle ergometer, is a safe
and effective intervention in preventing or attenuating the
decrease in functional exercise capacity that is associated
with prolonged ICU stay. Ninety critically ill patients with
expected prolonged stay were randomized to bedside
ergometer along with standardized therpay (physiotherapy).
Quadriceps force and functional status were assessed at ICU
discharge and hospital discharge. Six-minute walking
distance was measured at hospital discharge. There was no
adverse effect from the outcome among survivors and the
intervention group had significant functional improvement at
hospital discharge.
Another investigating party looked at the gender impact on
the outcomes of critically ill patients with nosocomial
infections [11]. It was a retrospective study based in an 18-
bed general ICU. Multivariable logistic regression analysis
was used to control for confounders in the evaluation of
gender impact on ICU death post-nosocomial infections.
Over 5,000 patient admissions were studied and the
conclusion was that female ICU patients developing noso-
comial infections seem to be at increased risk of ICU mortality,
after carefully controlling for other prognostic factors. Further
studies are needed to elucidate the pathophysiology
underlying this gender-related difference, to devise tailored
gender-specific therapies that might improve outcomes.
Alberda and colleagues [12] published a multicentre
observational study examining the relationship between the
amount of energy and protein administered during ICU stay
and clinical outcomes in critically ill patients, and the extent to
which pre-morbid nutritional status influenced this relation-
ship. The type and amount of nutrition received were
recorded daily for a maximum of 12 days. Patients were
followed prospectively to determine 60-day mortality and
ventilator-free days. Data were collected on 2,772 mechani-
cally ventilated patients who received an average of
1,034 kcal/day and 47 g protein/day. An increase of
1,000 cal/day was associated with reduced mortality. The
effect of increased calories associated with lower mortality
was observed in patients with a body mass index <25 and
≥35 with no benefit for patients with a body mass index of 25
to <35. Similar results were observed when comparing
increased protein intake and its effect on mortality. Perhaps
this is an intervention ICUs would want to seriously consider.
Acute kidney injury (AKI) has been the subject of NCEPOD
(National Confidential Enquiry into Patient Outcome and
Death) interest recently and data into provision of care and
outcomes have been published [13]. French investigators
Floccard and colleagues [14] have looked into 6-month
outcomes from AKI requiring renal replacement therapy
(RRT) in the ICU. AKI was defined by the RIFLE score.
Quality of life was assessed using the Short Form Health
Survey (SF-36) questionnaire. The results indicated that
patients who received RRT for AKI had a high mortality rate
6 months after RRT finished. Survivors (38%) at follow-up
had a lower level of quality of life compared to a reference
population, and their physical health was more affected than
their mental health. Most of the patients were independent in
daily activities and returned home. Twelve percent of
survivors were still receiving RRT at follow-up.
Acute necrotising pancreatitis is a serious condition with a
high mortality rate [15]. A recent prospective study [16]
assessed quality of life outcomes in 31 patients. Survivors
(68%) were assessed at 3, 6 and 12 months following hospital
discharge by an investigator blinded to their previous
treatment. Health related quality of life was assessed by the
Short Form Health Survey (SF-36) questionnaire and func-
tional outcome by the six-minute walk test. They concluded
that, in the first year after the insult, patients showed
improvement in their physical components of quality of life
and in their physical function, but their outcome at 12 months
was still poor compared to the general population. This
patient group in particular may benefit from a structured
rehabilitation programme continuing after hospital discharge.
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